中国药业2023，Vol.32Issue(23)：122-125,4.DOI:10.3969/j.issn.1006-4931.2023.23.028
布地格福联合乙酰半胱氨酸治疗老年慢性阻塞性肺疾病急性加重期临床观察
Clinical Observation of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol Combined with Acetylcysteine in the Treatment of Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
摘要
Abstract
Objective To investigate the clinical efficacy of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol combined with acetylcysteine in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 100 elderly patients with AECOPD admitted to the hospital from January 2019 to June 2021 were selected and divided into the observation group and the control group according to the random number table method,with 50 cases in each group.The patients in the control group were treated with acetylcysteine nebulization inhalation,on this basis,the patients in the observation group were treated with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol.Both groups were treated for two weeks.Results The total effective rate in the observation group was 94.00％,which was significantly higher than the 80.00％in the control group(P＜0.05).Compared with that in the control group,the relief time of clinical symptoms in the observation group was significantly shorter(P＜0.05).After treatment,the lung function indicators[forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),maximum voluntary ventilation volume(MVV),and FEV1/FVC]in the two groups were significantly higher than those before treatment(P＜0.05),and those in the observation group were significantly higher than those in the control group(P＜0.05);the scores of the modified British Medical Research Council dyspnea index grading scale(mMRC)and St.George's Respiratory Questionnaire(SGRQ)in the two groups were significantly lower than those before treatment(P＜0.05),and those in the observation group were significantly lower than those in the control group(P＜0.05);the levels of inflammatory factors such as tumor necrosis factor-α,interleukin-6,and C-reactive protein in the two groups were significantly lower than those before treatment(P＜0.05),and those in the observation group were significantly lower than those in the control group(P＜0.05).During the treatment,the incidence of adverse reactions in the observation group was comparable to that in the control group(22.00％vs.20.00％,P＞0.05).Conclusion Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol combined with acetylcysteine in the treatment of elderly patients with AECOPD has good clinical efficacy and safety,which can effectively improve the clinical symptoms,signs,and lung function of patients,improve quality of life,and reduce inflammatory factor levels.关键词
布地格福/乙酰半胱氨酸/老年慢性阻塞性肺疾病急性加重期/短期预后/肺功能Key words
Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol/acetylcysteine/elderly patients with acute exacerbation of chronic obstructive pulmonary disease/short-term prognosis/lung function分类
医药卫生引用本文复制引用
代海云,耿立惠..布地格福联合乙酰半胱氨酸治疗老年慢性阻塞性肺疾病急性加重期临床观察[J].中国药业,2023,32(23):122-125,4.基金项目
江苏省基础研究计划(自然科学基金)专项资金项目[SY202017]. （自然科学基金）
